Timing of resumption of immune checkpoint inhibitor therapy after successful control of immune-related adverse events in seven advanced non-small cell lung cancer patients
Sign Up to like & getrecommendations! Published in 2020 at "Anti-Cancer Drugs"
DOI: 10.1097/cad.0000000000000957
Abstract: Among advanced non-small cell lung cancer (NSCLC) patients in whom grade 2/3 immune-related adverse events (irAEs) that had developed during the initial immune checkpoint inhibitor (ICI) therapy had been successfully controlled, we experienced three patients… read more here.
Keywords: therapy; ici therapy; control; resumption ... See more keywords
SEVERE DE NOVO PUSTULAR PSORIASIFORM IMMUNE-RELATED ADVERSE EVENT ASSOCIATED WITH NIVOLUMAB TREATMENT FOR METASTATIC ESOPHAGEAL ADENOCARCINOMA.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of cutaneous pathology"
DOI: 10.1111/cup.14185
Abstract: Breakthrough targeted therapies have produced significant improvements in survival for cancer patients, but have a propensity to cause cutaneous immune-related adverse events (irAEs). Psoriasiform irAEs, representing about 4% of dermatologic toxicities associated with immune checkpoint… read more here.
Keywords: ici therapy; immune related; psoriasiform; pustular psoriasiform ... See more keywords
Incidence of immune checkpoint inhibitor–mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score–matched retrospective study
Sign Up to like & getrecommendations! Published in 2021 at "Journal for Immunotherapy of Cancer"
DOI: 10.1136/jitc-2021-002567
Abstract: Background and aims The risk of use of immune-mediated diarrhea and colitis (imDC) in patients with preexisting inflammatory bowel disease (IBD) is not fully understood. We report the incidence of imDC in these patients, and… read more here.
Keywords: ici therapy; mediated diarrhea; imdc patients; ibd ... See more keywords
Integration of proteomic and clinical data for the prediction of response to immune checkpoint inhibitor therapy in non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2021.39.15_suppl.e21110
Abstract: e21110 Background: Immune checkpoint inhibitor (ICI) therapy represents one of the most promising cancer treatments to date. However, despite unprecedented rates of durable response, only a small proportion of patients benefits from this approach. Major… read more here.
Keywords: therapy; checkpoint inhibitor; response; ici therapy ... See more keywords
Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis
Sign Up to like & getrecommendations! Published in 2021 at "Cardiology Research"
DOI: 10.14740/cr1319
Abstract: Immune checkpoint inhibitor (ICI) therapy has played an important role in the treatment of several groups of cancers. Although a life prolonging treatment, many side effects have been shown with ICI therapy. This study looked… read more here.
Keywords: immune checkpoint; ici therapy; therapy; clinical characteristics ... See more keywords
Early evaluation of subclinical cardiotoxicity in patients with lung cancer receiving immune checkpoint inhibitors by cardiovascular magnetic resonance: a prospective observational study
Sign Up to like & getrecommendations! Published in 2022 at "Quantitative Imaging in Medicine and Surgery"
DOI: 10.21037/qims-22-41
Abstract: Background Few studies have focused on the subclinical cardiotoxicity of immune checkpoint inhibitors (ICIs) in cancer patients. This study aimed to evaluate the manifestations of subclinical cardiotoxicity of ICI therapy using cardiovascular magnetic resonance (CMR)… read more here.
Keywords: ici therapy; group; second follow; ctrcd group ... See more keywords
A Lack of Biomarkers for Cardiac Complications of Immune Checkpoint Inhibitor Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Internal Medicine"
DOI: 10.2169/internalmedicine.5962-20
Abstract: Immune checkpoint inhibitors (ICIs) as modern cancer treatments have demonstrated significant clinical benefit for various malignancies. However, these agents may induce a wide spectrum of immune-related adverse events (irAEs) by enhancing immune responses in non-target… read more here.
Keywords: immune checkpoint; ici therapy; cardiac complications; iraes ... See more keywords
Dermatological Autoimmune Considerations of Immune Checkpoint Therapy
Sign Up to like & getrecommendations! Published in 2022 at "Biomedicines"
DOI: 10.3390/biomedicines10102339
Abstract: The most common immune-related adverse events (irAEs) involve the skin, and several serve as predictors of response to immune checkpoint inhibitor (ICI) therapy, especially in melanoma. Patients with pre-existing skin autoimmune diseases (ADs) have been… read more here.
Keywords: ici therapy; immune checkpoint; therapy; autoimmune considerations ... See more keywords
Initial Myeloid Cell Status Is Associated with Clinical Outcomes of Renal Cell Carcinoma
Sign Up to like & getrecommendations! Published in 2023 at "Biomedicines"
DOI: 10.3390/biomedicines11051296
Abstract: The therapeutic outcome of immune checkpoint inhibition (ICI) can be improved through combination treatments with ICI therapy. Myeloid-derived suppressor cells (MDSCs) strongly suppress tumor immunity. MDSCs are a heterogeneous cell population, originating from the unusual… read more here.
Keywords: cell; ici therapy; clinical outcomes; status ... See more keywords